Controlling Stake Sold for $400K, Co-CEOs Resign, Company Pivots to Oil & Gas
Summary
BIOFORCE NANOSCIENCES HOLDINGS, INC. announced a change of control with 79.65% of shares sold for $400,000, followed by the resignation of its Co-Chief Executive Officers and Vice-President, and a strategic pivot from the vitamin supplement industry to the oil and gas industry.
Key Events
-
Change of Control
On April 15, 2026, Merle Ferguson, a Director, sold his controlling interest of 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000. This formalizes the change of control previously hinted at in the May 19, 2026 10-Q filing.
-
Executive Resignations
On June 17, 2026, Co-Chief Executive Officers Steven Gagnon and John LaViolette, along with Vice-President Sasha Shapiro, resigned from their positions.
-
Interim Leadership & New Director
Richard Kaiser, already the Chief Financial Officer, Secretary, and Director, was appointed interim Chief Executive Officer on June 17, 2026. Scott Mager was appointed as a new Director effective June 15, 2026.
-
Strategic Business Pivot
The company is changing its business operations from the vitamin supplement industry to the oil and gas industry, with management actively evaluating new opportunities.
Analysis
This filing details a complete overhaul of the company's ownership, leadership, and business strategy. The sale of a controlling stake (79.65%) for a mere $400,000, coupled with the departure of multiple top executives and a speculative pivot to the oil and gas industry, signals extreme distress and a high-risk, uncertain future for a company already reporting zero revenue and a going concern warning.
At the time of this filing, BFNH was trading at $1.78 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $59.7M. The 52-week trading range was $0.16 to $2.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.